Moreover, the consensus group felt that if GLP-1 RAs and the novel dual GIP/GLP-1 RA tirzepatide show efficacy in the aforementioned subset of T1D patients, then it will be more likely that these drugs can eventually be widely approved for all T1D patients without posing a significant risk of hypoglycemia or DKA, especially in light of the current widespread use of CGM systems in this population and in view of the possible availability of continuous ketone monitoring (CKM) systems in the near future [213,214]. The gene discussed is GCG; the disease is Hypoglycemia.